COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,756 Articles (22,502 medRxiv, 8,254 bioRxiv)

Most recent first Previous |  Page 1463: Articles 14621-14630  | Next

Unusually high risks of COVID-19 mortality with age-related comorbidities: An adjusted method to improve the risk assessment of mortality using the comorbid mortality data.
Antos, A., Kwong, M. L., Balmorez, T., Villanueva, A., Murakami, S.
10.1101/2021.05.20.21257550 — Posted: 2021-05-21
Evaluating the effects of vaccine rollout policies in European countries: A simulation study
Barbounakis, P., Demiris, N., Pavlakis, G. N., Kontoyiannis, I., Sypsa, V.
10.1101/2021.05.19.21257486 — Posted: 2021-05-21
COVID-19 Mitigation Practices and COVID-19 Rates in Schools: Report on Data from Florida, New York and Massachusetts
Oster, E., Jack, R., Halloran, C., Schoof, J., McLeod, D.
10.1101/2021.05.19.21257467 — Posted: 2021-05-21
Detection of SARS-CoV-2 in saliva using tailed amplicon sequencing
Garoutte, A., Santiago-Rodriguez, T. M., Fehling, H. L., Iwasiow, R.
10.1101/2021.05.19.21257217 — Posted: 2021-05-21
Characterization of the Second Wave of the COVID-19 Pandemic in India: A Google Trends Analysis
Visaria, A., Polamarasetti, P., Reddy, S., Ali, A., Hameed, F. R., James, J., Akhtar, M., Islam, S., Raju, P., Thawani, R.
10.1101/2021.05.19.21257473 — Posted: 2021-05-21
Topic: Hyper immune Bovine Colostrum as a Low-Cost, Large-Scale Source of Antibodies against COVID-19
Nili, H., Bouzari, M., Attaran, H. R., Golab, N. G., Rabani, M.
10.1101/2021.05.20.444932 — Posted: 2021-05-20
Fluorescence signatures of SARS CoV-2 spike S1 proteins and an human ACE-2: excitation-emission maps and fluorescence lifetimes
Grzesiak, J., Fellner, L., Grünewald, K., Kölbl, C., Walter, A., Horlacher, R., Duschek, F.
10.1101/2021.05.20.444935 — Posted: 2021-05-20
A COVID-19 Community Vulnerability Index to drive precision policy in the US
Smittenaar, P., Stewart, N., Sutermaster, S., Coome, L., Dibner-Dunlap, A., Jain, M., Caplan, Y., Campigotto, C., Sgaier, S. K.
10.1101/2021.05.19.21257455 — Posted: 2021-05-20
Differential interferon-α subtype immune signatures suppress SARS-CoV-2 infection
Schuhenn, J., Meister, T. L., Todt, D., Bracht, T., Schork, K., Billaud, J.-N., Elsner, C., Heinen, N., Karakoese, Z., Haid, S., Kumar, S., Brunotte, L., Eisenacher, M., Chen, J., Yuan, Z., Pietschmann, T., Wiegmann, B., Beckert, H., Taube, C., Le-Trilling, V. T. K., Trilling, M., Krawczyk, A., Ludwig, S., Sitek, B., Steinmann, E., Dittmer, U., Sutter, K., Pfaender, S.
10.1101/2021.05.20.444757 — Posted: 2021-05-20
A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
Beumer, J., Geurts, M. H., Lamers, M. M., Puschhof, J., Zhang, J., van der Vaart, J., Mykytyn, A. Z., Breugem, T. I., Riesebosch, S., Schipper, D., van den Doel, P. B., de Lau, W., Pleguezuelos-Manzano, C., Busslinger, G., Haagmans, B. L., Clevers, H.
10.1101/2021.05.20.444952 — Posted: 2021-05-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).